OncoSil Medical
Australia - Macquarie ParkBiotechnology
Focus: OncoSil Medical is a publicly listed Australian biotechnology company focused on developing beta radiation devices for oncology, specifically targeting unresectable locally advanced pancreatic cancer. With 501-1000 employees, it operates as a specialized medical device biotech with a geographically concentrated headquarters in Macquarie Park.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
501-1000
Total Funding
$270M
Open Jobs
0
About OncoSil Medical
AI assessmentNot HiringNo open roles listed right now. Follow OncoSil Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Growth
Lead proprietary beta radiation device asset in post-market phase with ongoing observational registry (OSPREY) tracking real-world outcomes.
Pipeline & Clinical Trials
Help build intelligence for OncoSil Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.